Initial clinical observations from the use of a novel FGF23 neutralizing therapy34,35 in XLH have shown marked improvement in fatigue, muscle weakness and activity, suggesting that this therapy offers an advantage over standard therapy (oral Pi and calcitriol). This evidence concerns the gene FGF23 and X-linked hypophosphatemia.